Introduction
Multiple myeloma (MM), or myelomatosis, is a rare type of hematological malignancy that comprises ~10% of all hematological malignancies. It is a neoplastic proliferation characterized by the uncontrolled proliferation of plasma cells in the bone marrow that leads to bone osteolytic destruction, anemia, recurrent infections and renal impairment. The incidence of MM is ~3-4 per 100,000 individuals (1) . Common presenting features of MM include bone pain and bone fractures, anemia, increased susceptibility to infections, hypercalcemia, neurological manifestations, hyperviscosity syndrome and renal failure (1, 2) .
Although MM is usually confined to the bone marrow, it may occasionally infiltrate into other tissues (3, 4) , and this is known as extramedullary plasmacytoma (EMP). To the best of our knowledge, there are no recommended guidelines for the treatment of EMP. Treatment options include surgery, chemotherapy and radiotherapy, either alone or combination (5) . Local radiotherapy is the preferred therapeutic modality for EMP owing to its documented radiosensitivity (6) . However, previous studies indicated that a combination treatment may provide the best results (7). The majority of EMPs involve the head and neck regions (8) , although different anatomical sites, including the gastrointestinal tract, central nervous system, thyroid gland and breast may also be affected (7) . However, it is rare that EMPs present initially with simultaneous intracranial and renal infiltration.
The current study reports a case of primary intracranial and renal plasmacytoma in a 76-year-old male patient. Written informed consent was obtained from the patient's family and ethical approval was obtained from the committee of Cangzhou Central Hosptial (Cangzhou, China). 
Case report
The patient presented to the Cangzhou Central Hospital in March 2014, complaining of swelling over the right side of the forehead, which had been slowly progressing during the 3 months prior to the date of admission, and was associated with dizziness and weakness. The patient did not present bone pain or a tendency for abnormal bleeding, and physical examination excluded lymphadenopathy and organomegally. A tense globular swelling of 5.0-6.5 cm in size was observed over the right frontal area, adhered to the underlying skull and skin. Contrast magnetic resonance imaging (MRI) suggested an osteolytic skull lesion with intracranial extension (Fig. 1A ).
Abdominal enhanced computed tomography (CT) scanning revealed a large tumor mass extending around and into the kidneys ( Fig. 2A ). Thus, a right renal biopsy was performed, and histopathological analysis of the tumor sample confirmed it to be plasmacytoma. Immunohistochemical staining was performed using cluster of differentiation (CD)38 and CD138 antibodies purchased from Beijing Xiya Jinqiao Biological Technology Co., Ltd. (Beijing, China). All stains were completed using a BenchMark machine (serial no. 815132; Ventana Medical Systems, Inc., Tucson, AZ, USA) and images were captured with an Olympus BX41 microscope (Olympus, Tokyo, Japan) and Image-Pro Plus software (Media Cybernetics, Inc., Rockville, MD, USA). Immunohistochemistry indicated that the tumor cells were positive for CD38 and CD138 (Fig. 3) . The blood count demonstrated a hemoglobin concentration of 108 g/l, a white cell count of 6.07x10 9 cells/l with no abnormal cells and a platelet count of 143x10 9 cells/l. The levels of serum creatinine, calcium and phosphorus were within the normal range (NR). The erythrosedimentation rate was 113 mm/h, and the level of serum β2 microglobulin was 4,499 µmol/l (NR, 0.9-2.7 µmol/l). The total serum protein concentration was 83 g/l (NR, 60-83 g/l), and the levels of 
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Bence-Jones (monoclonal) protein, indicating a diagnosis of MM (9) . Bone marrow aspiration revealed 4% restriction of plasma cells, and whole body bone emission CT demonstrated multiple abnormal distribution of tracer concentration. Consequently, a diagnosis of MM was established. The patient and his relatives refused further examination, surgical operation and radiotherapy, due to the patient's age and body condition. Therefore, the patient was subjected to chemotherapy, and was administered 2 cycles of cyclophosphamide and thalidomide in combination with dexamethasone. Follow-up imaging 4 months later revealed nearly complete disappearance of the intracranial tumor mass (Fig. 1B) and renal infiltration (Fig. 2B) . The clinical condition also improved, and the patient experienced a complete recovery.
Discussion
EMP is a rare malignant neoplasm that develops due to uncontrolled plasma cell proliferation and monoclonal plasmacytic infiltration (10) . EMPs may coexist with MM, presenting as the main symptom, developing during the course of MM, or occasionally occurring as isolated tumors (11, 12) . Intracranial extramedullary plasmacytomas account for 4% of all primary plasma cell tumors (3) . In patients with a diagnosis of MM, the presence of intracranial EMPs, as a result of the metastatic spread of MM, is rare, occurring in 1% of all the reported cases (13, 14) . To the best of our knowledge, <30 cases of renal plasmacytoma have been reported in the literature previously (15) . In the cases of renal EMPs, the tumor mass is mostly confined to this anatomical area, and <10% involve other organs besides the kidney (16, 17) . Thus, to the best of our knowledge, the initial presentation of an EMP displaying intracranial and renal infiltration simultaneously, such as in the present case, has not been previously described.
The diagnosis of EMP is more complicated than that of MM, and requires radiological, hematological, biochemical and histological examinations. Due to the absence of typical clinical symptoms and evidence from specific laboratory tests, a diagnosis of EMP may be delayed or missed, with potentially serious consequences for the patient. In the present case, EMP was diagnosed based on the clinical symptoms of the patient, alongside the imaging findings and the results of the serum Ig electrophoresis and the histopathological analyses of tissue biopsy and bone marrow aspirate.
To date, there are no specific guidelines for the treatment of EMP presenting with MM. The current treatment options for EMP include surgery, chemotherapy and radiotherapy, either alone or in combination (3, 15) . If the tumor is located in an area with restricted surgical access, a complete resection with fractionated radiotherapy at the tumor site may be a good option for intracranial plasmacytomas. However, a number of case reports have highlighted the use of systemic chemotherapy and radiotherapy as the most important part of the treatment (18, 19) . Recent studies on the fundamental molecular mechanisms responsible for MM cell growth and survival have led to the introduction of novel classes of pharmacological agents, including immunomodulatory drugs and proteasome inhibitors (20) . In the present case, combined chemotherapy was selected as the treatment for EMP, due to the patient's age and body condition. In this context, chemotherapy may be an attractive option for certain cases, for example when the treatment is aimed at improving the quality of life of patients rather than at increasing the survival rate, particularly in elderly patients.
In conclusion, the simultaneous presentation of EMP in the kidney and head is rare. Thus, the present case report may aid in the diagnosis and treatment of future cases of EMPs. Figure 3 . Immunohistochemical analysis of the infiltrate indicated strongly positive staining for (A) CD38 (magnification, x40) and (B) CD138 (magnification, x100). CD, cluster of differentiation.
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